文献速递前列腺癌

前列腺癌的流行病学与预防

Epidemiology and Prevention of Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2021-10-26

该综述基于IARC GLOBOCAN 2020年185国数据描述前列腺癌地理分布,并检索2010–2020年文献评估危险因素。2020年全球估计新发超1414000例、死亡超375000例;家族史、种族和遗传综合征是最强危险因素,可改变因素可能影响发病与死亡风险,但除早期诊断外缺乏明确预防指征。

要点

  • 2020年全球前列腺癌估计新发超1414000例,年龄标化发病率31/10万,终生累积风险3.9%。
  • 2020年全球估计死亡超375000例,年龄标化死亡率7.7/10万,加勒比地区最高(28)。
  • 家族史、遗传性综合征和种族是最强危险因素;可改变因素可能影响发病与死亡风险。

核心结论

  • 家族史、种族和遗传性综合征是前列腺癌明确危险因素。
  • 可改变危险因素可能影响前列腺癌发病和死亡风险,但除早期诊断外缺乏明确预防指征。

研究设计与样本

  • 从IARC GLOBOCAN数据库获取2020年185个国家前列腺癌估计发病率、死亡率和患病率。
  • 通过MEDLINE、EMBASE和Scopus检索2010至2020年英文文献以识别前列腺癌危险因素。

主要发现

  • 2020年全球估计新发前列腺癌超1414000例,年龄标化发病率31/10万,终生累积风险3.9%。
  • 北欧全年龄发病率年龄标化率最高(83),南中亚最低(6.3)。
  • 2020年全球估计死亡超375000例,总体死亡率年龄标化率7.7/10万,加勒比最高(28),南中亚最低(3.1)。
  • 代谢综合征与前列腺癌发病风险、高级别疾病和不良病理相关;糖尿病和紫外线暴露与前列腺癌发病率呈负相关。
  • 吸烟和肥胖可能增加前列腺癌特异性死亡率,规律体力活动可能降低疾病进展;5α还原酶抑制剂与前列腺癌发病率降低相关,但未显示对总死亡率的影响。

关键数值与推荐

  • 2020年全球前列腺癌估计新发超1414000例,年龄标化发病率31/10万(终生累积风险3.9%)。
  • 2020年全球前列腺癌估计死亡超375000例,总体死亡率年龄标化率7.7/10万。
  • 北欧全年龄发病率年龄标化率最高(83),南中亚最低(6.3);加勒比死亡率年龄标化率最高(28),南中亚最低(3.1)。

临床怎么用

  • 应结合家族史、种族和遗传性综合征识别前列腺癌高风险男性。
  • 可改变危险因素(如代谢综合征、吸烟、肥胖、体力活动)可能影响发病与死亡风险,但尚不足以作为明确预防指征。
  • 除早期诊断外,目前缺乏明确的前列腺癌预防指征以降低死亡率。

局限性

  • 文献检索限于2010至2020年英文发表文章。
  • 除早期诊断外,可改变危险因素用于预防的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Worldwide, prostate cancer (PCa) represents the second most common solid tumor in men. OBJECTIVE: To assess the geographical distribution of PCa, epidemiological differences, and the most relevant risk factors for the disease. EVIDENCE ACQUISITION: Estimated incidence, mortality, and prevalence of PCa for the year 2020 in 185 countries were derived from the IARC GLOBOCAN database. A review of English-language articles published between 2010 and 2020 was conducted using MEDLINE, EMBASE, and Scopus to identify risk factors for PCa. EVIDENCE SYNTHESIS: In the year 2020, there were over 1414000 estimated new cases of PCa worldwide, with an age-standardized rate (ASR) incidence of 31 per 100000 (lifetime cumulative risk: 3.9%). Northern Europe has the highest all-age incidence ASR (83), while the lowest ASR was in South-Central Asia (6.3). In the year 2020, there were over 375000 estimated deaths worldwide, and the overall mortality ASR was 7.7 per 100000, with the highest ASR in the Caribbean (28) and the lowest in South-Central Asia (3.1). Family history, hereditary syndromes, and race are the strongest risk factors for PCa. Metabolic syndrome was associated with the risk of developing PCa, high-grade disease, and adverse pathology. Diabetes and exposure to ultraviolet rays were found to be inversely associated to PCa incidence. Cigarette smoking and obesity may increase PCa-specific mortality, while regular physical activity may reduce disease progression. Although 5-alpha reductase inhibitors are known to be associated with a reduced incidence of PCa, available studies failed to show an effect on overall mortality. CONCLUSIONS: Family history, race, and hereditary syndromes are well-established risk factors for PCa. Modifiable risk factors may impact the risk of developing PCa and that of dying from the disease, but little evidence exist for any clear indication for prevention other than early diagnosis to reduce PCa mortality. PATIENT SUMMARY: Prostate cancer (PCa) rates vary profoundly worldwide, with incidence and mortality rates being highest in Northern Europe and Caribbean, respectively. South-Central Asia has the lowest epidemiological burden. Family history, race, and hereditary syndromes are well-established risk factors for PCa. Modifiable risk factors may impact the risk of developing PCa and that of dying from the disease itself, but little evidence exist for any clear indication for prevention other than early diagnosis to reduce PCa mortality.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Leni R, Bray F, et al. Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol. 2021. PMID: 34716119. doi:10.1016/j.euo.2021.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。